<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05692167</url>
  </required_header>
  <id_info>
    <org_study_id>MKSU 50-11-3</org_study_id>
    <nct_id>NCT05692167</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine in Topical Versus Peribulbar Anesthesia for Cataract Surgery</brief_title>
  <official_title>Dexmedetomidine as an Additive to Topical Versus Peribulbar Anesthesia for Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kafrelsheikh University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kafrelsheikh University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare efficacy of dexmedetomidine as an additive to topical&#xD;
      versus peribulbar anesthesia for cataract surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ocular surgery may be performed under topical, regional, or general anesthesia. The first&#xD;
      recorded use of regional anesthesia for surgery was the instillation of cocaine into the&#xD;
      conjunctival sac in 1884 by an Austrian ophthalmologist.&#xD;
&#xD;
      Davis and Mandel in 1986 described the peribulbar block, peribulbar block has delayed onset&#xD;
      and need a higher volume of local anesthetic (LA) than a retrobulbar block. But the&#xD;
      peribulbar block is away from intra-conal space and so produce fewer complication.&#xD;
&#xD;
      Dexmedetomidine is used as adjuvant to LA drugs in peripheral nerve block, brachial plexus&#xD;
      block and intrathecal anesthesia with satisfactory results. A more recent study using&#xD;
      dexmedetomidine (50 μg) with the peribulbar block before cataract surgery demonstrated an IOP&#xD;
      decrease similar to IV dexmedetomidine administration and greater than a peribulbar block&#xD;
      without dexmedetomidine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2023</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inadvertent eye movement</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>Asses intra-ocular pressure (IOP) before injection of baseline and after a complete akinesia of the globe before surgical incision.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anesthesia-related complications</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>The patients will be asked whether the cataract surgery was more or less painful than having the needle used for intravenous infusions inserted into the back of the hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>Numeric Rating Scale will be applied to grade the pain where 0 = no pain and 10 = extreme pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain during and after the surgery</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>Immediately after surgery, patients will be asked to grade the pain felt during the operation, including the pain felt after delivery of topical or peribulbar anaesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional anesthesia during surgery and surgeon</measure>
    <time_frame>During surgery</time_frame>
    <description>The dose of additional needed anesthesia (fentanyl 0.5 µg/kg) during surgery will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative difficulties</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>The surgeon will also be requested to grade any difficulties encountered during surgery immediately after the operation, using a 4-point scale, where 1 = no difficulty and 4 = extremely difficult</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Dexmedetomidine</condition>
  <condition>Cataract Surgery</condition>
  <condition>Peribulbar</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Topical dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reginal dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical dexmedetomidine</intervention_name>
    <description>Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic</description>
    <arm_group_label>Topical dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reginal dexmedetomidine</intervention_name>
    <description>Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block</description>
    <arm_group_label>Reginal dexmedetomidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status classification I or II who&#xD;
             scheduled for eye surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are younger than 18 years&#xD;
&#xD;
          -  The usual contraindications for regional anesthesia such as patients refusing LA&#xD;
&#xD;
          -  Clotting abnormalities&#xD;
&#xD;
          -  Impaired mental status&#xD;
&#xD;
          -  Allergy to any of the study medications&#xD;
&#xD;
          -  patients had the severe cardiac disease&#xD;
&#xD;
          -  chronic obstructive lung disease and a history of sleep apnea&#xD;
&#xD;
          -  contraindications to the use of dexmedetomidine&#xD;
&#xD;
          -  history or significant cardiovascular disease risk factors&#xD;
&#xD;
          -  significant coronary artery disease or any known genetic predisposition&#xD;
&#xD;
          -  history of any kind of drug allergy&#xD;
&#xD;
          -  drug abuse&#xD;
&#xD;
          -  psychological or other emotional problems&#xD;
&#xD;
          -  special diet or lifestyle&#xD;
&#xD;
          -  clinically significant abnormal findings in physical examination&#xD;
&#xD;
          -  electrocardiographic (ECG) or laboratory screening&#xD;
&#xD;
          -  known systemic disease requiring the use of anticoagulants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed F Algyar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of Anaesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Kafrelsheikh University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed F Algyar, MD</last_name>
    <phone>00201111645345</phone>
    <phone_ext>047</phone_ext>
    <email>mohammad.algaiar@med.kfs.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mohammed Fouad Mohamed Algyar</name>
      <address>
        <city>Kafrelsheikh</city>
        <zip>33516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohammed F Algyar, MD</last_name>
      <phone>00201111645345</phone>
      <phone_ext>047</phone_ext>
      <email>mohammad.algaiar@med.kfs.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>January 11, 2023</last_update_submitted>
  <last_update_submitted_qc>January 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kafrelsheikh University</investigator_affiliation>
    <investigator_full_name>Mohamed Fouad Algyar</investigator_full_name>
    <investigator_title>Lecturer of Anaesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Kafrelsheikh University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be available under a reasonable request from the corresponding author</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>One year after the end of the study</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

